Bad News: Zeposia, which is already approved by the FDA for treating multiple sclerosis and ulcerative colitis, failed to hit its target endpoint in its Phase III clinical trial of Crohn's disease.
https://news.bms.com/news/corporate...-to-Severe-Active-Crohns-Disease/default.aspx
https://news.bms.com/news/corporate...-to-Severe-Active-Crohns-Disease/default.aspx